[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
July 8, 1998

Viagra Leads as Rivals Are Moving Up

Author Affiliations

Not Available

Not Available

JAMA. 1998;280(2):119-120. doi:10.1001/jama.280.2.119

SOME ERECTILE dysfunction (ED) researchers and pharmaceutical manufacturers may be suffering a bit of sildenafil envy these days, but recent findings give hope to those wishing to slow the Viagra prescription juggernaut.

Researchers at last month's 93rd Annual Meeting of the American Urology Association (AUA), held in San Diego, Calif, presented studies promoting alternatives to Viagra (sildenafil citrate), the cGMP-specific type 5 phosphodiesterase (PDE5) inhibitor manufactured by New York, NY–based Pfizer Inc.

First Page Preview View Large
First page PDF preview
First page PDF preview